[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ZA200204863B - Suspension comprising oxcarbazepine. - Google Patents

Suspension comprising oxcarbazepine.

Info

Publication number
ZA200204863B
ZA200204863B ZA200204863A ZA200204863A ZA200204863B ZA 200204863 B ZA200204863 B ZA 200204863B ZA 200204863 A ZA200204863 A ZA 200204863A ZA 200204863 A ZA200204863 A ZA 200204863A ZA 200204863 B ZA200204863 B ZA 200204863B
Authority
ZA
South Africa
Prior art keywords
oxcarbazepine
suspension
Prior art date
Application number
ZA200204863A
Other languages
English (en)
Inventor
Juergen Sigg
Michael Billington
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10866648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200204863(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA200204863B publication Critical patent/ZA200204863B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200204863A 1999-12-20 2002-06-28 Suspension comprising oxcarbazepine. ZA200204863B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9930058.4A GB9930058D0 (en) 1999-12-20 1999-12-20 Organic compounds

Publications (1)

Publication Number Publication Date
ZA200204863B true ZA200204863B (en) 2003-03-17

Family

ID=10866648

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200204863A ZA200204863B (en) 1999-12-20 2002-06-28 Suspension comprising oxcarbazepine.

Country Status (34)

Country Link
US (1) US8119148B2 (fr)
EP (2) EP1437127A1 (fr)
JP (2) JP4588281B2 (fr)
KR (2) KR20040098034A (fr)
CN (1) CN1216594C (fr)
AR (1) AR030175A1 (fr)
AT (1) ATE269694T1 (fr)
AU (1) AU777619B2 (fr)
BE (2) BE1013706A5 (fr)
BR (1) BR0016524A (fr)
CA (1) CA2390029C (fr)
CO (1) CO5261608A1 (fr)
CZ (1) CZ302737B6 (fr)
DE (1) DE60011809T2 (fr)
DK (1) DK1239832T3 (fr)
ES (1) ES2223641T3 (fr)
FR (1) FR2802423B1 (fr)
GB (1) GB9930058D0 (fr)
HK (1) HK1050474A1 (fr)
HU (1) HU226486B1 (fr)
IL (2) IL149498A0 (fr)
IT (1) ITMI20002717A1 (fr)
MX (1) MXPA02006142A (fr)
MY (1) MY126868A (fr)
NO (1) NO331990B1 (fr)
NZ (1) NZ518755A (fr)
PE (1) PE20010933A1 (fr)
PL (1) PL201331B1 (fr)
PT (1) PT1239832E (fr)
RU (1) RU2277912C2 (fr)
SK (1) SK287553B6 (fr)
TR (2) TR200402419T4 (fr)
WO (1) WO2001045671A2 (fr)
ZA (1) ZA200204863B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds
DE10224086A1 (de) * 2002-05-31 2003-12-11 Bayer Ag Pharmazeutische Zubereitungen zur oralen Anwendung enthaltend wirkstoffbeladene Ionentauscherharze sowie strukturviskose Gelbildner als Verdicker
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
US7815924B2 (en) 2002-09-20 2010-10-19 Fmc Corporation Cosmetic composition containing microcrystalline cellulose
AU2004268381B2 (en) 2003-09-03 2009-06-18 Novartis Ag Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
WO2007007182A2 (fr) * 2005-07-08 2007-01-18 Aurobindo Pharma Limited Formes galeniques solides d'agent antiepileptique
EP1906937B1 (fr) 2005-07-22 2016-10-19 Rubicon Research Pvt Ltd. Nouvelle composition de comprimé dispersible
JP5253381B2 (ja) * 2006-04-26 2013-07-31 スパーナス ファーマシューティカルズ インコーポレイテッド シグモイド放出プロファイルを有するオキサカルバゼピンの制御放出製剤
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
KR20080076667A (ko) * 2007-02-15 2008-08-20 주식회사 중외제약 요변성 약학 조성물
IN2012DN02379A (fr) * 2009-09-10 2015-08-21 Bial Portela & C A Sa
CN104288104A (zh) * 2014-09-24 2015-01-21 万特制药(海南)有限公司 奥卡西平干混悬剂及其制备方法
JP6902033B2 (ja) 2015-12-30 2021-07-14 アダマス ファーマシューティカルズ， インコーポレイテッド 発作−関連障害の処置のための方法および組成物
CN109010322A (zh) * 2018-07-13 2018-12-18 山东达因海洋生物制药股份有限公司 一种包含奥卡西平的口腔分散膜剂及其制备方法
CN115487145B (zh) * 2022-10-10 2023-09-01 上海奥科达医药科技股份有限公司 一种奥卡西平口服混悬液及其制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH500196A (de) 1969-03-10 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
US4004029A (en) * 1974-05-13 1977-01-18 The Upjohn Company Compositions and method for treating epilepsy and convulsions
US4431641A (en) * 1980-10-17 1984-02-14 Ciba-Geigy Corporation Pharmaceutical compositions having antiepileptic and antineuralgic action
RO81639A2 (fr) * 1981-02-27 1983-06-01 Intreprinderea De Medicamente "Biofarm",Ro Procede d'obtention d'un poudre suspendable orale d'ampiciline
CH649080A5 (de) * 1981-04-16 1985-04-30 Ciba Geigy Ag 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz.
US4427681A (en) * 1982-09-16 1984-01-24 Richardson-Vicks, Inc. Thixotropic compositions easily convertible to pourable liquids
JPS60204713A (ja) 1984-03-30 1985-10-16 Zenyaku Kogyo Kk 水性懸濁組成物
US4693901A (en) * 1985-12-10 1987-09-15 Cardinal Biological, Ltd. Shelf stable dairylike products
GB8618847D0 (en) * 1986-08-01 1986-09-10 Smith Kline French Lab Pharmaceutical formulations
IL86211A (en) * 1987-05-04 1992-03-29 Ciba Geigy Ag Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it
ATE87476T1 (de) 1988-11-10 1993-04-15 Ciba Geigy Ag Fluessige orale formulierung.
GB9102579D0 (en) 1991-01-24 1991-03-27 Glaxo Group Ltd Compositions
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
GB9219524D0 (en) * 1992-09-15 1992-10-28 Smithkline Beecham Plc Novel composition
FR2699077B1 (fr) 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
WO1994016693A1 (fr) * 1993-01-19 1994-08-04 Warner-Lambert Company Formulation ci-981, orale, stable et son procede de preparation
FR2702148B1 (fr) 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
FR2702149B1 (fr) 1993-06-03 1995-04-07 Rhone Poulenc Rorer Sa Application de la lamotrigine dans le traitement du neuro-sida.
FR2702151B1 (fr) 1993-06-03 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
NZ295132A (en) 1994-10-14 1998-06-26 Janssen Pharmaceutica Nv Sabeluzole aqueous suspension having ph from 8 to 10
DE4443966A1 (de) * 1994-12-09 1996-06-13 Basf Ag Thermoplastische Formmassen
PT101732B (pt) 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
IT1277663B1 (it) 1995-09-28 1997-11-11 Crinos Industria Farmaco Sospensioni acquose stabili di mesalazina per uso topico
PT101876B (pt) * 1996-05-27 1999-09-30 Portela & Ca Sa Novos derivados de 10,11-di-hidro-10-oxo-5h-dibenzo(b,f)azepina-5-carboxamida
IT1286496B1 (it) 1996-11-20 1998-07-15 Leetrim Ltd Dublin Composizione farmaceutica orale ad attivita' antipiretica,analgesica ed antiinfiammatoria
US6037380A (en) * 1997-04-11 2000-03-14 Fmc Corporation Ultra-fine microcrystalline cellulose compositions and process
US6146876A (en) * 1999-06-11 2000-11-14 Millennium Pharmaceuticals, Inc. 22025, a novel human cyclic nucleotide phosphodiesterase
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
HUP0203782A2 (hu) 2003-03-28
US8119148B2 (en) 2012-02-21
MXPA02006142A (es) 2002-12-05
MY126868A (en) 2006-10-31
SK8652002A3 (en) 2002-12-03
IL149498A0 (en) 2002-11-10
HK1050474A1 (en) 2003-06-27
NO331990B1 (no) 2012-05-21
PT1239832E (pt) 2004-10-29
RU2277912C2 (ru) 2006-06-20
TR200402419T4 (tr) 2004-12-21
AU777619B2 (en) 2004-10-21
GB9930058D0 (en) 2000-02-09
CO5261608A1 (es) 2003-03-31
SK287553B6 (sk) 2011-01-04
AR030175A1 (es) 2003-08-13
IL149498A (en) 2011-05-31
US20030004155A1 (en) 2003-01-02
EP1239832B1 (fr) 2004-06-23
CN1216594C (zh) 2005-08-31
ATE269694T1 (de) 2004-07-15
DE60011809D1 (en) 2004-07-29
ITMI20002717A1 (it) 2002-06-15
KR100496368B1 (ko) 2005-06-21
HU226486B1 (en) 2009-03-02
KR20020062658A (ko) 2002-07-26
KR20040098034A (ko) 2004-11-18
NO20022849L (no) 2002-06-14
BR0016524A (pt) 2002-09-24
BE1014502A5 (fr) 2003-11-04
EP1239832A2 (fr) 2002-09-18
RU2002119210A (ru) 2004-02-27
EP1437127A1 (fr) 2004-07-14
PL355535A1 (en) 2004-05-04
DK1239832T3 (da) 2004-08-09
NO20022849D0 (no) 2002-06-14
CA2390029A1 (fr) 2001-06-28
CA2390029C (fr) 2010-01-26
AU2511801A (en) 2001-07-03
PE20010933A1 (es) 2001-09-17
NZ518755A (en) 2004-04-30
PL201331B1 (pl) 2009-03-31
FR2802423A1 (fr) 2001-06-22
DE60011809T2 (de) 2005-06-30
JP2006312651A (ja) 2006-11-16
CZ302737B6 (cs) 2011-10-12
TR200201459T2 (tr) 2002-09-23
FR2802423B1 (fr) 2005-03-25
ES2223641T3 (es) 2005-03-01
CZ20022138A3 (cs) 2002-09-11
JP4588281B2 (ja) 2010-11-24
WO2001045671A2 (fr) 2001-06-28
CN1411367A (zh) 2003-04-16
HUP0203782A3 (en) 2005-01-28
BE1013706A5 (fr) 2002-06-04
JP2003518036A (ja) 2003-06-03
WO2001045671A3 (fr) 2002-02-21

Similar Documents

Publication Publication Date Title
ZA200001665B (en) Suspension device.
MXPA01013362A (es) Anticuerpos de humano, anti-alfavbeta3 recombinantes, °cidos nucleicos que codifican a los mismos y metodos de uso.
EG24361A (en) 4-pyrimiding1-n-acy1.l.phenlalanines
ZA200200477B (en) 2-pyrazolin-5-ones.
ZA200202537B (en) Pour-on-formulations.
ZA200201829B (en) New phenylpiperazines.
ZA200203762B (en) 4-pyridinyl-IN-acyl-L-phenylalanines.
ZA200204863B (en) Suspension comprising oxcarbazepine.
HK1046366A1 (en) Ziprasidone suspension.
EP1185819A4 (fr) Conception de suspension pour siege
AU6345800A (en) Stirrup suspension
GB9906447D0 (en) Suspension arrangements
GB2348405B (en) Vehicle suspension
DE60044882D1 (en) Ie
AU3485600A (en) Suspension harness
MXPA02000261A (es) Aminoindanos novedosos.
GB2338498B (en) Suspension arrangement
ZA200204581B (en) Nitro-sulfobenzamides.
GB0116051D0 (en) Vehicle suspension
SI1239832T1 (en) Suspension comprising oxcarbazepine
HK1031254A1 (en) Tachogragh.
ZA200001460B (en) Support.
GB9929736D0 (en) Suspension point
MXPA02005346A (es) Antigenos de cryptosporidium esporozoito.
GB9900040D0 (en) Suspension system